Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT02987166 Completed - Solid Tumor Clinical Trials

HDCRT Plus Pembrolizumab in Advanced Malignancies

UVA-AM-001
Start date: March 21, 2017
Phase: Phase 1
Study type: Interventional

This study is a pilot study to evaluate high-dose conformal radiation therapy (HDCRT) administered in combination with pembrolizumab in patients with solid tumors.

NCT ID: NCT02986100 Completed - Solid Tumor Clinical Trials

Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

AME
Start date: November 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered [14C] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation

NCT ID: NCT02974738 Active, not recruiting - Solid Tumor Clinical Trials

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Start date: December 7, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors

NCT ID: NCT02968485 Recruiting - Solid Tumor Clinical Trials

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This aim of study to assess the safety and tolerability of SHR7390 and to define the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors. To evaluate the pharmacokinetics of SHR7390 in patients with advanced solid tumors. To study the effects of food on the pharmacokinetic parameters of SHR7390. To assess the antitumor activity of SHR7390 in patients with advanced solid tumors preliminarily and recommend reasonable dosage regimen for the follow-up clinical trial.

NCT ID: NCT02966171 Terminated - Solid Tumor Clinical Trials

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

Start date: January 2017
Phase: Phase 1
Study type: Interventional

This is a first-time-in-human, phase I, open-label, dose-escalation study of HMPL-453 in patients with advanced or metastatic solid malignancies who have failed or are intolerable to standard therapies or for whom no standard therapies exist. There are preliminary two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). We will decide whether to conduct stage 2 or not one month after the last patient included in stage 1.

NCT ID: NCT02963389 Completed - Lymphoma Clinical Trials

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

Start date: October 4, 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma patients

NCT ID: NCT02963168 Recruiting - Solid Tumor Clinical Trials

A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

Start date: April 20, 2017
Phase: Phase 1
Study type: Interventional

This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel. No control group has been included.

NCT ID: NCT02959619 Completed - Solid Tumor Clinical Trials

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Start date: March 6, 2017
Phase: Phase 1
Study type: Interventional

This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer

NCT ID: NCT02953782 Completed - Colorectal Cancer Clinical Trials

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Start date: November 2, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

NCT ID: NCT02950103 Terminated - Solid Tumor Clinical Trials

Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients

Start date: August 2016
Phase: Phase 2
Study type: Interventional

Synthetic phosphoethanolamine is a primary amine which has a critical role in the biosynthesis of cell membranes. Pre-clinical models have shown potential anticancer activity.